Naujausios naujienos ir straipsniai apie genetinius tyrimus
May 22, 2026
Researchers have developed a gene-based blood test that may help detect early signs of melanoma recurrence. This non-invasive test has the potential to improve patient outcomes and reduce mortality rates associated with skin cancer.
May 22, 2026
University of Kent. "Scientists discover skincare compound that kills drug-resistant bacteria." ScienceDaily. ScienceDaily, 21 April 2026. <www.sciencedaily.com/releases/2026/04/260420014738.htm>...
May 22, 2026
Researchers at the University of Kent have identified a compound found in skincare products that exhibits potent antibacterial properties against drug-resistant bacteria. This discovery may lead to new treatments for infections caused by these "superbugs".
May 22, 2026
Florida Atlantic University. "Blind to the burn: Misconceptions about skin cancer risk in the US." ScienceDaily. ScienceDaily, 12 March 2025. <www.sciencedaily.com/releases/2025/03/250312124316.htm...
May 22, 2026
A recent study reveals that many Americans are unaware of their risk for skin cancer, perpetuating misconceptions about sun protection and skin damage. As a result, individuals may be neglecting to take necessary precautions against this common and potentially deadly disease.
May 22, 2026
Scripps Research Institute. "Enzyme engineering opens door to novel therapies for Parkinson's, cancers and other hard-to-target protein diseases." ScienceDaily. ScienceDaily, 27 March 2025. <www.sc...
May 22, 2026
Scripps Research Institute. "Enzyme engineering opens door to novel therapies for Parkinson's, cancers and other hard-to-target protein diseases." ScienceDaily. ScienceDaily, 27 March 2025. <www.sc...
May 22, 2026
Scripps Research Institute. "Enzyme engineering opens door to novel therapies for Parkinson's, cancers and other hard-to-target protein diseases." ScienceDaily. ScienceDaily, 27 March 2025. <www.sc...
May 21, 2026
Researchers at NYU Langone Health have developed a gene-based blood test that may be able to detect early signs of melanoma recurrence. This non-invasive test has shown promise in identifying patients who are at high risk of cancer returning.
